Needham maintained its Buy rating and raised the price target on Cloudflare (NET) to $160 from $110 ahead of the company's ...

KLA (NASDAQ:KLAC – Free Report) had its target price lifted by Needham & Company LLC from $800.00 to $830.00 in a report ...

Hologic (HOLX – Research Report) received a Hold rating and price target from Needham analyst Michael Matson today. The company’s shares ...

In a report released today, Ryan Koontz from Needham maintained a Hold rating on Silicom (SILC – Research Report). The company’s shares closed ...

Fintel reports that on February 3, 2025, Needham downgraded their outlook for Hologic (NasdaqGS:HOLX) from Buy to Hold.

Needham & Company LLC upgraded shares of Viavi Solutions (NASDAQ:VIAV – Free Report) from a hold rating to a buy rating in a ...

Cloudflare Inc . (NYSE: NYSE:NET) saw its price target increased by Needham, from $110 to $160, with a continued Buy rating ...

CEO Mattias Perjos said surgical perfusion has “been a struggling category” since an FDA consent decree forced Getinge off the U.S. market in 2015.

Technological innovations in steam power, electricity and microprocessors drove the first industrial revolution.

Investors often prefer to invest in shares held by company insiders, as management is typically more aligned with the company’s success and shareholder interests. Currently, insiders own just 0.02% of ...

On January 28th, analysts at Needham and Company reiterated a Buy rating on the stock with a $90 price target. The buy rating comes on the heels of the company inking a strategic partnership with ...